Published in Pharmacotherapy on February 01, 2002
Self-administered outpatient parenteral antimicrobial therapy: a report of three years experience in the Irish healthcare setting. Eur J Clin Microbiol Infect Dis (2009) 0.93
Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin. Clinicoecon Outcomes Res (2013) 0.87
Outpatient parenteral antimicrobial therapy practices among adult infectious disease physicians. Infect Control Hosp Epidemiol (2014) 0.81
The Impact of an Infectious Diseases Transition Service on the Care of Outpatients on Parenteral Antimicrobial Therapy. J Pharm Technol (2013) 0.78
Vancomycin and home health care. Emerg Infect Dis (2005) 0.75
Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. Crit Care (2014) 0.75
Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis (2003) 4.09
Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol (2005) 2.31
Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in nonneutropenic patients. Ann Pharmacother (2007) 2.28
Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med (2002) 2.07
Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. Clin Infect Dis (2002) 1.74
Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. Chest (2005) 1.72
Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother (2002) 1.64
Pharmacy cost sharing, antiplatelet therapy utilization, and health outcomes for patients with acute coronary syndrome. Am J Manag Care (2010) 1.54
Reference group choice and antibiotic resistance outcomes. Emerg Infect Dis (2004) 1.51
Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis (2005) 1.45
Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother (2007) 1.40
Characteristics of patients with healthcare-associated infection due to SCCmec type IV methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol (2006) 1.40
Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes. Pharmacotherapy (2007) 1.35
Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol (2004) 1.31
Prediction model to identify patients with Staphylococcus aureus bacteremia at risk for methicillin resistance. Infect Control Hosp Epidemiol (2003) 1.30
Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother (2003) 1.28
Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis (2010) 1.26
Glaucoma management among individuals enrolled in a single comprehensive insurance plan. Ophthalmology (2005) 1.26
A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacotherapy (2005) 1.18
Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes. Pharmacotherapy (2007) 1.08
The direct and indirect cost burden of acute coronary syndrome. J Occup Environ Med (2011) 1.08
Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol (2004) 1.06
Rates of discontinuation and change of glaucoma therapy in a managed care setting. Am J Manag Care (2002) 1.05
Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. Am J Manag Care (2002) 1.00
A new measure of patient satisfaction with ocular hypotensive medications: the Treatment Satisfaction Survey for Intraocular Pressure (TSS-IOP). Health Qual Life Outcomes (2003) 0.99
Variations in treatment among adult-onset open-angle glaucoma patients. Ophthalmology (2005) 0.94
Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a nationally representative managed-care population. Curr Med Res Opin (2009) 0.91
Observed time between prescription refills for newer ocular hypotensive agents: the effect of bottle size. Am J Ophthalmol (2004) 0.91
Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study. Clin Ther (2003) 0.89
An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures. Pharmacoeconomics (2003) 0.88
Management of hypertension and hypercholesterolaemia in primary care in The Netherlands. Curr Med Res Opin (2005) 0.87
Economic consequences of ACS-related rehospitalizations in the US. Curr Med Res Opin (2010) 0.87
Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia. Clin Infect Dis (2005) 0.85
Clinical outcomes and cost minimization with an alternative dosing regimen for meropenem in a community hospital. Pharmacotherapy (2007) 0.85
Effect of early clopidogrel discontinuation on rehospitalization in acute coronary syndrome: results from two distinct patient populations. Am J Health Syst Pharm (2011) 0.84
Bioavailability of gatifloxacin by gastric tube administration with and without concomitant enteral feeding in critically ill patients. Crit Care Med (2003) 0.82
Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a single integrated health network. Curr Med Res Opin (2009) 0.82
Measuring patient persistency with drug therapy using methods for the design and analysis of natural history studies. Am J Manag Care (2002) 0.82
Improving adherence with antimicrobial therapy for respiratory tract infections: a discussion of directly observed therapy (DOT) and short-course therapies. Am J Ther (2013) 0.81
Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients. Pharmacotherapy (2010) 0.80
Early clinical experience with anidulafungin at a large tertiary care medical center. Pharmacotherapy (2008) 0.79
Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever. Pharmacotherapy (2009) 0.79
Direct medical costs associated with using vancomycin in methicillin-resistant Staphylococcus aureus infections: an economic model. Curr Med Res Opin (2004) 0.79
Comparative effectiveness of antiarrhythmic drugs on cardiovascular hospitalization and mortality in atrial fibrillation. J Comp Eff Res (2013) 0.78
An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects. Int J Antimicrob Agents (2004) 0.78
Drug treatment discontinuation and achievement of target blood pressure and cholesterol in United Kingdom primary care. Curr Med Res Opin (2007) 0.77
Disposition of cefepime in the central nervous system of patients with external ventricular drains. Pharmacotherapy (2003) 0.77
Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies. Diagn Microbiol Infect Dis (2006) 0.76
Adherence to dyslipidemia treatment guidelines in diabetic patients. AMIA Annu Symp Proc (2006) 0.75
Health care resource utilization associated with treatment of penicillin-susceptible and -nonsusceptible isolates of Streptococcus pneumoniae. Pharmacotherapy (2003) 0.75
Economic consequences of severe bleeding in patients with acute coronary syndrome in the USA. Adv Ther (2010) 0.75
Use of insurance claims data to assess outpatient antimicrobial therapy for gram-positive infections. Pharmacotherapy (2002) 0.75
Estimation of potential cost savings associated with reduced rates of cardiovascular hospitalization among atrial fibrillation/flutter patients treated with dronedarone in the ATHENA trial. Am J Ther (2014) 0.75
A practice-based research network focused on comparative effectiveness research in type 2 diabetes management. Postgrad Med (2013) 0.75